Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: the phase 1/randomised phase 2 SCALOP-2 trial

<p><strong>Background:</strong> The multi-centre two-stage SCALOP-2 trial (ISRCTN50083238) assessed whether dose escalation of consolidative chemoradiotherapy (CRT) or concurrent sensitization using the protease inhibitor nelfinavir improve outcomes in locally advanced pancreatic c...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar:	Mukherjee, S, Qi, C, Shaw, R, Jones, CM, Bridgewater, JA, Radhakrishna, G, Patel, N, Holmes, J, Virdee, PS, Tranter, B, Parsons, P, Falk, S, Wasan, HS, Ajithkumar, TV, Holyoake, D, Roy, R, Scott-Brown, M, Hurt, CN, O'Neill, E, Sebag-Montefiore, D, Maughan, TS, Hawkins, MA, Corrie, P
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	Elsevier 2024

Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: the phase 1/randomised phase 2 SCALOP-2 trial

Benzer Materyaller